News
Having secured deals with AstraZeneca and Novartis, Niowave is constructing a second facility to meet rising demand for actinium-225, which can be used to develop next-generation radiopharmaceuticals.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
The holds were lifted by the FDA in July of 2020, but the company’s timeline had been severely set back by the miscalculation.
The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Newpath is guided by the ethos: “Do the right thing and good things will happen.”
Several life sciences companies and life science-focused real estate firms have announced expansion plans as 2021 comes to an end.
At Harbinger, Hahn will oversee the development of the Bio-AI diagnostics platform dubbed HarbingerHx, in hopes of detecting cancer in a patient before it is visible or symptomatic.
The counterclaim by an alleged victim of MIT professor David Sabatini said she was coerced into sex and that Sabatini’s laboratory had a “toxic and sexually charged” environment.
Vyera Pharmaceuticals agreed to pay $40 million to settle federal allegations to radically increase the price of toxoplasmosis drug Daraprim and prevent generic competition.
Neurocrine Biosciences and Acadia Pharmaceuticals posted positive top-line results from their respective Phase III trials on major neurological diseases.
Researchers are working to develop new treatments for Alzheimer’s disease and dementia and improve the already existing ones. Find out more here.